Johnson & Johnson (NYSE: JNJ) has marked its 59th consecutive year of dividend growth by declaring a quarterly dividend of $1.13 per share, reinforcing its status as a Dividend Aristocrat. In Q1 2022, the company experienced a significant 6.3% year-over-year growth in pharmaceutical sales, reaching $12.8 billion, alongside consumer health revenue of $3.58 billion. With shares increasing from $54 to $176 and a dividend yield of 2.67%, Johnson & Johnson demonstrates robust financial health and a strong commitment to shareholder returns.
“Johnson & Johnson · has managed to increase its dividend · 59 years in a row”
“Johnson & Johnson · is a Dividend Aristocrat · paid increasing dividends for at least 25 years”
“Johnson & Johnson · is one of the top Big Pharma companies · true · true”
“Johnson & Johnson (NYSE:JNJ) · reported a 6.3% year-over-year growth in its pharmaceutical sales to · $12.8 billion · in Q1 2022”
“Johnson & Johnson (NYSE:JNJ) · declared a quarterly dividend of · $1.13 per share · on April 19”
“Johnson & Johnson · is one of the · top Big Pharma companies · specializing in pharmaceuticals, consumer products, and medical devices”
“Johnson & Johnson · reported growth in pharmaceutical sales · in Q1 2022 · 6.3%”
“Johnson & Johnson · reported consumer health revenue · in Q1 2022 · $3.58 billion”
“Johnson & Johnson · declared a quarterly dividend · on April 19 · $1.13 per share”
“Johnson & Johnson · has a streak of dividend growth · consecutively · 60 years”
“Johnson & Johnson · stock's dividend yield · on June 17 · 2.67%”
“Johnson & Johnson, Abbott Laboratories, Cardinal Health · have made it to the list of · Dividend Aristocrats · companies that have paid increasing dividends for at least 25 years”
